Sana Biotechnology (SANA) has released an update to notify the public and investors about an entry into a material definitive agreement.
Sana Biotechnology, Inc. has initiated a significant public offering, partnering with major underwriters such as Morgan Stanley and Goldman Sachs to sell over 17 million shares and pre-funded warrants, potentially raising around $156.6 million. The offering, scheduled to close on February 12, 2024, includes an additional option for underwriters to purchase extra shares. The proceeds are set to fuel the company’s growth, with the deal featuring standard closing conditions and indemnification obligations. This move marks a pivotal financial milestone for Sana Biotechnology and is carried out under an effective registration statement with the SEC.
For further insights into SANA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
